

**KEYWORD INDEX**

#

[177Lu]Lu-edotreotide B012

80S ribosome inhibitors A030

A

Actionable mutations A011

acute lymphoblastic leukemia B030

ACUTE LYMPHOBLASTIC LEUKEMIA A040

ADAR A027

Adolescent and Young Adult tumor B034

Alectinib A017

ALK-fusion A017

ALL B035

alternative splicing B022

Alveolar rhabdomyosarcoma A022

Antibody-drug conjugate (ADC) A033

Aptamers B049

Atypical Teratoid Rhabdoid Tumors B016

B

B cell Immunity A042

Bcl-xL PROTAC A025

big data B046

biomarker A001

biomarkers A004, A028, B035

BIOMARKERS B003

BRAF A032, B019

BRD4 B013

C

Cancer Associated Fibroblasts B009

Cancer predisposition A007

Cancer Predisposition Syndromes A045, B039

Cancer Stem Cells B007

CAR T Cell Therapy A039

CAR T cells A018



AACR Special Conference in Cancer Research

**DISCOVERY AND INNOVATION IN PEDIATRIC CANCER:
FROM BIOLOGY TO BREAKTHROUGH THERAPIES**

In association with the AACR Pediatric Cancer Working Group (PCWG)

September 25-28 | Boston, MA

AACR
American Association
for Cancer Research®

250402D

KEYWORD INDEX

CAR T-cell therapy	B028
CAR-T cells	A038
Catecholamine signalling	B026
CDK12	A037, B015
CDK8	A022
Cellular energetics	B045
cGAS-STING-IFN	B007
Chemoresistance	A025
Chemotherapy	B006
Chemotherapy Persistence	B016
Childhood cancer	A045
choroid plexus tumor	B038
circulating tumor DNA	A001
circulating tumor DNA (ctDNA)	A013
Circulating tumor DNA (ctDNA)	B008
cloud computing	B033
combination therapies	B023
Combination therapy	A048
Congenital chronic myeloid leukemia	B004
Craniopharyngioma	B009
CRISPR-Cas9	B024
Cross-Disease Research	B032
ctDNA	A009
Curation	A021

D

data analysis	A016
Data management	B047
Data Sharing	B032
DELTA133TP53	B005
development	A012
differentiation	A020
Diffuse Intrinsic Pontine Glioma (DIPG)	A039
Diffuse midline glioma	B040, B041
Diffuse Midline Glioma	A046
Diffuse Midline Gliomas	A050



AACR Special Conference in Cancer Research

**DISCOVERY AND INNOVATION IN PEDIATRIC CANCER:
FROM BIOLOGY TO BREAKTHROUGH THERAPIES**

In association with the AACR Pediatric Cancer Working Group (PCWG)

September 25-28 | Boston, MA

AACR
American Association
for Cancer Research®

250402D

KEYWORD INDEX

DIPG	A036
DNA damage response	B015
DNA Pooling	B029
double negative T cells	B030
Drug combinations	A026
drug resistance	B042
DSRCT	A037

E

E3 ligases	A023
Early Mobilization	B051
Early-Onset Pediatric Cancer	B029
ECM remodeling	B009
EP300	B043
Ependymoma	A042, A049
epigenetic	A043
epigenetic regulation	B046
Epigenetic therapeutics	A026
Epigenetic therapy	A048
epigenetics	A020
Epigenetics	B043
Ewing sarcoma	A015, A016, A035, B018, B048
Ewing Sarcoma	B014
Exosomes	B044
extracellular vesicles	A004

F

FGFR alterations	B020
FGFR inhibitors	B020
FLC, PROTAC, Antisense	A031
flow cytometry	B030
Focused Ultrasound	A038
fusion oncokinase	B034
Fusion oncoproteins	A008

G



KEYWORD INDEX

GB13	A036
GBM	A036
GD2 expression	B027
Genetic predisposition	A006
GENETIC VARIANTS	A040
Genomic profiling	A011
genomic profiling	B001
genomics	B033
Germline Cancer Genetics	A044
Glioma	B024, B037
Glycosylation	B019

H

HCT Pediatrics	B051
hepatoblastoma	B036
Hepatoblastoma	B008, B010
High-grade glioma	B011
High-throughput drug screening	A026
histone deacetylase inhibitors	B014
histotripsy	A029
human embryonic stem cells	A035

I

IMMUNE MICROENVIRONMENT	A040
Immunoliposomes	B017
Immunology	B025
immunotherapy	A018
Immunotherapy	B027
IMMUNOTHERAPY	B003
Information dissemination	B047
iopofosine I 131	A019
Ipatasertib.	A034

J

There were no keywords in this range.



KEYWORD INDEX

K

There were no keywords in this range.

L

Late effects	B006
leukemogenesis	B035
Li-Fraumeni Syndrome	B039
Liquid Biopsy	A009
liquid biopsy fragmentomics	A013
Liquid biopsy fragmentomics	B008
long-read sequencing	B002
Low-grade glioma	A008, B011
low-grade gliomas	B020

M

medium-chain triglyceride	B054
machine learning	B002
Maintenance Therapy	B017
malignant pleural effusion	B054
mesenchymal embryonic stem cells	A035
Metabolic plasticity	B045
Metabolic Starvation	B010
metastasis	B052
Metastasis and Dedifferentiation	B010
Microenvironment	B037
MicroRNA	B028
miRNA	A047
Molecular diagnostics	B004
Molecular Oncology	A044
Molecular profiling	A005
molecularly-targeted therapy	A003
Mosaicism	A007
mTOR	B036
mutant MYOD1	A033
myogenic differentiation	A022
Myogenic differentiation.	A034



AACR Special Conference in Cancer Research

**DISCOVERY AND INNOVATION IN PEDIATRIC CANCER:
FROM BIOLOGY TO BREAKTHROUGH THERAPIES**

In association with the AACR Pediatric Cancer Working Group (PCWG)

September 25-28 | Boston, MA

AACR
American Association
for Cancer Research®

250402D

KEYWORD INDEX

N

neuroblastoma	A029, A043
Neuroblastoma	A009, A025, B026, B027, B044, B054
Newborn Screening	B039
Nf1	B011
NGS	A003, B053
NOTCH	B038
novel inhibitor	B021
novel targets	A020
NRF2	B036
NTRK fusions	A021

O

Oncogenic fusions	A032
Oncogenicity	A021
Osteosarcoma	B043

P

p53 reactivation	A046
Paracrine signaling	B040
Pathogenesis	B034
pediatric	A017, A043
PEDIATRIC B-ALL	B005
Pediatric brain cancer	B028
pediatric cancer	A006
pediatric cancer biomarkers	B021
Pediatric cancer drug discovery	A030
pediatric CNS tumors	B022
Pediatric Genomics	B032
pediatric high-grade glioma	A019
pediatric leukemia	B001
pediatric low-grade glioma	A014
pediatric low-grade gliomas	B023
Pediatric Oncology	B050
Pediatric osteosarcoma	B052



KEYWORD INDEX

Pediatric solid tumor	A005
Pediatric solid tumors	A011
Peptide Therapy	B017
Philadelphia chromosome	B004
PI3K pathway	A050
Pilocytic astrocytoma	A032, B019
PKR	A027
post-translational modification	A047
PPM1D	A046, A050, B041
Precision medicine	A005
Precision oncology	A002
Promyelocytic Leukemia	A047
Psychosocial support	B050
public-private partnerships	A030
Puerto Rico	B052

Q

There were no keywords in this range.

R

radiopharmaceutical therapy	B012
RAS/RAF/MEK	A028
RB1-altered tumors	B021
RD3	B044
receptor tyrosine kinases	A023
regulatory	B031
Replication	B024
Resistance	B013
Ret	B014
Retinal degeneration protein 3	B045
retinoblastoma	A012
Rhabdoid Tumour	B025
rhabdomyosarcoma	A028, B042
Rhabdomyosarcoma	A033, A041, B007, B013, B015
Rhadomyosarcoma.	A034
RNA sequencing	A002

**KEYWORD INDEX****S**

sarcoma	A003
Secondary data analysis	B047
secondary findings	A006
Senescence	B040
Signaling	B037
single-cell RNA sequencing	A014
single-cell RNA-sequencing	A016
solid tumor	A018
Somatic and Germline molecular profiling	A044
Somatic mutational signatures	B006
Somatic Variation	B053
somatostatin receptor positive	B012
SOX2	B038
Spatial transcriptomics	B025
splicing	B031
Structural Variants	B053
synovial sarcoma	A004

T

T cell exhaustion	B026
Targeted combination therapy	B018
Targeted drug delivery	B049
targeted inhibitors	B023
Targeted Next-Generation Sequencing (tNGS)	B029
targeted radiotherapy	A019
targeted therapies	A023
targeted therapy	A037, B001
Tertiary lymphoid structures	A041
Therapeutic storytelling	B050
therapeutics	A024
TP53	B005
TP53-mutant AML	A027
Transcriptional regulation	A049
transcriptome	B002



KEYWORD INDEX

transcriptomics	A014
Transcriptomics	A015
TRANSCRIPTOMICS	B003
tumor biology	B046
Tumor immune microenvironment	A041
tumor microenvironment	A029
Tumor Microenvironment	A038, A042
Tumor Microenvironment (TME)	A039
Tumor Recurrence	B016
tumor-specific antigens	B022
Two-hit hypothesis	A045

U

There were no keywords in this range.

V

validation	A024
variants	B031
virtual institute	B048

W

Whole genome sequencing	A002
whole-genome methylation sequencing	A013
workshop	A024

X

There were no keywords in this range.

Y

There were no keywords in this range.

Z

ZFTA::NCOA2	A049
-------------	------